Core Insights - Eli Lilly and Incyte announced positive results from a late-stage study of oral baricitinib for adolescents with severe alopecia areata, showing significant hair regrowth improvements at Week 36 [1][6] Study Results - The phase III BRAVE-AA-PEDS study involved 257 patients, with 60% of those on 4 mg and 36.9% on 2 mg showing at least a 50% improvement in their condition, compared to 5.7% on placebo [3] - For scalp hair coverage, 42.4% on 4 mg and 27.4% on 2 mg achieved at least 80% coverage, versus 4.5% on placebo; 36.5% on 4 mg and 21.4% on 2 mg reached 90% or more coverage compared to 2.3% on placebo [3] - Eyebrow regrowth showed 50% improvement in the 4 mg group and 24.1% in the 2 mg group, while eyelash regrowth was 42.9% for 4 mg and 25.5% for 2 mg, compared to 14% on placebo [4] Drug Profile - Baricitinib, marketed as Olumiant, is a once-daily oral JAK inhibitor already approved for adults with severe alopecia areata and has shown potential for addressing unmet medical needs in adolescents [2][6] - The drug is also approved for treating moderate to severe rheumatoid arthritis and atopic dermatitis in various countries, generating sales of $957.4 million in 2024, reflecting a 4% year-over-year increase [10] Market Performance - Eli Lilly's shares have increased by 9.2% over the past three months, outperforming the industry growth of 5.2% [4]